Barclays Forecasts Strong Price Appreciation for Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health (NASDAQ:PAHC) had its price objective hoisted by equities research analysts at Barclays from $13.00 to $20.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has an “underweight” rating on the stock. Barclays‘s price target suggests a potential downside of 20.85% from the stock’s current price.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. assumed coverage on shares of Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price for the company. Bank of America lifted their price objective on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $16.50.

Phibro Animal Health Trading Up 0.8 %

NASDAQ PAHC opened at $25.27 on Tuesday. The firm has a market capitalization of $1.02 billion, a PE ratio of 58.77, a P/E/G ratio of 0.66 and a beta of 0.51. The stock’s 50 day moving average is $22.57 and its 200 day moving average is $19.61. Phibro Animal Health has a twelve month low of $9.49 and a twelve month high of $25.98. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. The firm had revenue of $273.16 million for the quarter, compared to analysts’ expectations of $262.44 million. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. Research analysts forecast that Phibro Animal Health will post 1.59 earnings per share for the current fiscal year.

Insider Activity at Phibro Animal Health

In other Phibro Animal Health news, Director E Thomas Corcoran bought 5,000 shares of Phibro Animal Health stock in a transaction on Wednesday, September 4th. The stock was acquired at an average price of $20.02 per share, with a total value of $100,100.00. Following the acquisition, the director now owns 25,000 shares in the company, valued at approximately $500,500. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 50.07% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of PAHC. BNP Paribas Financial Markets raised its holdings in shares of Phibro Animal Health by 3.1% during the third quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock valued at $548,000 after purchasing an additional 729 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Phibro Animal Health during the 3rd quarter valued at $70,000. FMR LLC boosted its stake in shares of Phibro Animal Health by 22.7% in the 3rd quarter. FMR LLC now owns 39,310 shares of the company’s stock worth $885,000 after buying an additional 7,270 shares during the last quarter. Algert Global LLC grew its holdings in shares of Phibro Animal Health by 521.1% in the third quarter. Algert Global LLC now owns 71,335 shares of the company’s stock worth $1,606,000 after acquiring an additional 59,850 shares during the period. Finally, Segall Bryant & Hamill LLC lifted its holdings in Phibro Animal Health by 1.7% in the third quarter. Segall Bryant & Hamill LLC now owns 174,569 shares of the company’s stock valued at $3,931,000 after acquiring an additional 2,971 shares during the period. Institutional investors own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.